Evidence map›Paper›PMID 36860867›Full record

ArticleFrontiers in immunology2023

Single-cell clonal tracking of persistent T-cells in allogeneic hematopoietic stem cell transplantation.

Benedikt Obermayer, Luisa Keilholz, Thomas Conrad, Marco Frentsch, Igor-Wolfgang Blau, Lam Vuong, Stella Lesch, Kamran Movasshagi, Carola Tietze-Stolley, Lucie Loyal and 9 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Recent advances in the pathophysiology and treatment of GVHD.International journal of hematology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 1 country.

Benedikt ObermayerCore Unit Bioinformatics (CUBI), Berlin Institute of Health at Charite - Universitätsmedizin Berlin, Berlin, Germany.
Luisa KeilholzDepartment of Hematology, Oncology, and Tumor Immunology, Charite - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Thomas ConradCore Unit Genomics, Berlin Institute of Health at Charite - Universitätsmedizin Berlin, Berlin, Germany.
Marco FrentschDepartment of Hematology, Oncology, and Tumor Immunology, Charite - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Igor-Wolfgang BlauDepartment of Hematology, Oncology, and Tumor Immunology, Charite - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Lam VuongDepartment of Hematology, Oncology, and Tumor Immunology, Charite - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Stella LeschDepartment of Hematology, Oncology, and Tumor Immunology, Charite - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Kamran MovasshagiDepartment of Hematology, Oncology, and Tumor Immunology, Charite - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Carola Tietze-StolleyDepartment of Hematology, Oncology, and Tumor Immunology, Charite - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Lucie LoyalBIH Center for Exploratory Diagnostic Sciences (EDS), Berlin Institute of Health at Charite - Universitätsmedizin Berlin, Berlin, Germany.
Larissa HenzeBIH Center for Exploratory Diagnostic Sciences (EDS), Berlin Institute of Health at Charite - Universitätsmedizin Berlin, Berlin, Germany.
Olaf PenackDepartment of Hematology, Oncology, and Tumor Immunology, Charite - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Ulrik StervboBIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charite - Universitätsmedizin Berlin, Berlin, Germany.
Nina BabelBIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charite - Universitätsmedizin Berlin, Berlin, Germany.
Simon HaasDepartment of Hematology, Oncology, and Tumor Immunology, Charite - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Dieter BeuleCore Unit Bioinformatics (CUBI), Berlin Institute of Health at Charite - Universitätsmedizin Berlin, Berlin, Germany.
Lars BullingerDepartment of Hematology, Oncology, and Tumor Immunology, Charite - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Friedrich WittenbecherDepartment of Hematology, Oncology, and Tumor Immunology, Charite - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Il-Kang NaDepartment of Hematology, Oncology, and Tumor Immunology, Charite - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin · DEFreie Universität Berlin · DEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEHumboldt-Universität zu Berlin · DERuhr University Bochum · DEMax Delbrück Center · DETechnische Universität Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The critical balance between intended and adverse effects in allogeneic hematopoietic stem cell transplantation (alloHSCT) depends on the fate of individual donor T-cells. To this end, we tracked αβT-cell clonotypes during stem cell mobilization treatment with granulocyte-colony stimulating factor (G-CSF) in healthy donors and for six months during immune reconstitution after transfer to transplant recipients. More than 250 αβT-cell clonotypes were tracked from donor to recipient. These clonotypes consisted almost exclusively of CD8

Indexed as

Drug-Related Side Effects and Adverse ReactionsHematopoietic Stem Cell TransplantationCell TrackingHematopoietic Stem Cell MobilizationHumansStem Cell Transplantationallogeneic HSCTclonal trackingleukemiascRNAseqT-cellstransplantation

Identifiers

PMID36860867
PMCPMC9969884
OpenAlexW4320485255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.